Gufic Biosciences Limited (GUFICBIO) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹480.95 (+10.23% day change)
Key ratios
- P/E ratio
- 75.15
- P/B ratio
- 4.13
- ROE (%)
- 9.66
- ROCE (%)
- 14.61
- Debt/Equity
- 0.61
- Dividend yield (%)
- 0.04
- Market cap (₹ Cr)
- 4,823.09
Forensic checks
Piotroski F-Score: 4/9 · Altman Z-Score: 7.45 · Beneish M-Score: -2.27
InvestSights quality score
56.4/100 — Average (descriptive data-driven composite; not a recommendation)
Latest earnings call (Q1 FY27)
AI summary: The central signal was that Indore is moving from commissioning drag toward operating leverage, while Gufic simultaneously upgrades its product and commercial mix. Q1 FY27 delivered revenue of ₹260.8 crores, EBITDA of ₹47.2 crores and an EBITDA margin of 18.09%, which Pranav Choksi characterised as the start of margin improvement. The next phase depends less on basic capacity…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.